FR24C1027I2 - Agents antifongiques et leurs utilisations - Google Patents

Agents antifongiques et leurs utilisations

Info

Publication number
FR24C1027I2
FR24C1027I2 FR24C1027C FR24C1027C FR24C1027I2 FR 24C1027 I2 FR24C1027 I2 FR 24C1027I2 FR 24C1027 C FR24C1027 C FR 24C1027C FR 24C1027 C FR24C1027 C FR 24C1027C FR 24C1027 I2 FR24C1027 I2 FR 24C1027I2
Authority
FR
France
Prior art keywords
antifungal agents
antifungal
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1027C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAPP PHARMACEUTICAL GROUP Ltd
Original Assignee
NAPP PHARMACEUTICAL GROUP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAPP PHARMACEUTICAL GROUP Ltd filed Critical NAPP PHARMACEUTICAL GROUP Ltd
Publication of FR24C1027I1 publication Critical patent/FR24C1027I1/fr
Application granted granted Critical
Publication of FR24C1027I2 publication Critical patent/FR24C1027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR24C1027C 2011-03-03 2024-06-20 Agents antifongiques et leurs utilisations Active FR24C1027I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448807P 2011-03-03 2011-03-03
PCT/US2012/027451 WO2012119065A2 (fr) 2011-03-03 2012-03-02 Agents antifongiques et leurs utilisations

Publications (2)

Publication Number Publication Date
FR24C1027I1 FR24C1027I1 (fr) 2024-08-30
FR24C1027I2 true FR24C1027I2 (fr) 2025-05-23

Family

ID=46758514

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1027C Active FR24C1027I2 (fr) 2011-03-03 2024-06-20 Agents antifongiques et leurs utilisations

Country Status (22)

Country Link
US (6) US8722619B2 (fr)
EP (2) EP2680873B1 (fr)
JP (4) JP5809296B2 (fr)
CN (2) CN103889221B (fr)
CA (2) CA3053850A1 (fr)
CY (2) CY1119709T1 (fr)
DK (1) DK2680873T3 (fr)
ES (1) ES2645074T3 (fr)
FI (1) FIC20240022I1 (fr)
FR (1) FR24C1027I2 (fr)
HR (1) HRP20171579T8 (fr)
HU (2) HUE036778T2 (fr)
LT (2) LT2680873T (fr)
LU (1) LUC00351I2 (fr)
NL (1) NL301280I2 (fr)
NO (1) NO2680873T3 (fr)
PL (1) PL2680873T3 (fr)
PT (1) PT2680873T (fr)
RS (1) RS56426B1 (fr)
SI (1) SI2680873T1 (fr)
SM (1) SMT201700460T1 (fr)
WO (1) WO2012119065A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5809296B2 (ja) 2011-03-03 2015-11-10 シーチェイド ファーマシューティカルズ，インコーポレーテッド 抗真菌薬及びそれらの使用
KR102236462B1 (ko) * 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
US20160213742A1 (en) * 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
MX2016014216A (es) * 2014-04-28 2017-05-30 Univ Central Florida Res Found Inc Composiciones, metodos para producir una composicion, y metodos de uso.
WO2016201283A1 (fr) * 2015-06-12 2016-12-15 Cidara Therapeutics, Inc. Agents antifongiques
WO2017049102A1 (fr) * 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Méthodes de traitement d'infections fongiques
CN106674333B (zh) * 2015-11-06 2020-10-27 博瑞生物医药（苏州）股份有限公司 一种环肽类抗真菌化合物及其制备方法
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
ES2955711T3 (es) 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
CA3036553A1 (fr) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Procedes de traitement d'une maladie pulmonaire a l'aide de proteines inhibitrices d'inter-alpha
US20210002346A1 (en) * 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (fr) * 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
CA3069423C (fr) 2017-07-12 2025-04-15 Napp Pharmaceutical Group Limited Formulations pour le traitement des infections fongiques
CA3103619A1 (fr) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthese d'un agent antifongique d'echinocandine
WO2020086931A1 (fr) * 2018-10-25 2020-04-30 Cidara Therapeutics, Inc. Polymorphe d'un agent antifongique de type échinocandine
US12466856B2 (en) 2019-12-06 2025-11-11 Shanghai Senhui Medicine Co., Ltd. Echinocandin analogues and preparation method therefor
US20240262866A1 (en) * 2021-06-03 2024-08-08 Shanghai Senhui Medicine Co., Ltd. Method for preparing anidulafungin derivative
CN115850383A (zh) * 2022-12-15 2023-03-28 江苏九阳生物制药有限公司 一种雷扎芬净纯化方法
CN116903706B (zh) * 2023-06-13 2024-05-17 深圳市祥根生物有限公司 一种棘白菌素类药物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) * 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
CA2161149A1 (fr) * 1993-05-04 1994-11-10 James M. Balkovec Ether-oxydes de cyclohexapeptidyle et d'aminoalkyle
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
AU7874494A (en) * 1993-09-22 1995-04-10 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
CA2211138A1 (fr) 1995-01-26 1996-08-01 Merck & Co., Inc. Nouveaux cyclohexapeptides antifongiques
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
PE63998A1 (es) 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
USRE38984E1 (en) 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
IL143563A0 (en) * 1998-12-09 2002-04-21 Lilly Co Eli Purification of echinocandin cyclopeptide compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE294571T1 (de) 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
EP1172105A4 (fr) 1999-04-16 2002-09-04 Fujisawa Pharmaceutical Co Compositions antifongiques
US6610822B2 (en) 2000-09-01 2003-08-26 Merck & Co., Inc. Purification process
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
WO2005014777A2 (fr) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Procedes et compositions pour augmenter l'efficacite de substances actives d'un point de vue biologique
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
EP1654036B1 (fr) 2003-07-22 2007-12-26 Theravance, Inc. Utilisation d'un agent antifongique a base d'echinocandines conjointement avec un agent antibacterien glycopeptidique
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US8753819B2 (en) 2005-07-26 2014-06-17 Rutgers, The State University Of New Jersey Assays for resistance to echinocandin-class drugs
WO2007113386A1 (fr) * 2006-03-31 2007-10-11 Karyon-Ctt Ltd Conjugués peptidiques
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010096868A1 (fr) 2009-02-25 2010-09-02 Stiefel Research Australia Pty Ltd Composition de mousse à usage topique
EP2427477B1 (fr) * 2009-05-07 2014-02-26 DSM Sinochem Pharmaceuticals Netherlands B.V. Procédé de préparation de cyclopeptides
NO2470168T3 (fr) 2009-08-26 2018-06-30
EP2470190A4 (fr) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc Dérivés d échinocandine
EP2525831B1 (fr) 2010-01-22 2019-05-15 Ascendis Pharma A/S Liens de promédicaments à base de carbamates liés à un support
JP5809296B2 (ja) 2011-03-03 2015-11-10 シーチェイド ファーマシューティカルズ，インコーポレーテッド 抗真菌薬及びそれらの使用
WO2013017691A1 (fr) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Inhibiteurs de cahgtlp destinés à être utilisés dans le traitement de la candidiase
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
KR102236462B1 (ko) 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
US20150320675A1 (en) 2013-01-18 2015-11-12 University Of Utah Research Foundation Modified Release Osmotic Pump for PH-Responsive Drug Delivery
WO2014124504A1 (fr) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions et méthodes de traitement de biofilms
WO2014145109A1 (fr) 2013-03-15 2014-09-18 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Conjugués de médicament-séquence de liaison du sucre
JP6254257B2 (ja) 2013-05-01 2017-12-27 ネオクリ ピーティーワイ リミテッド 細菌感染を処置するための方法
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2017049105A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations pour le traitement d'infections fongiques
WO2017049102A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Méthodes de traitement d'infections fongiques
CN108883152A (zh) 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
ES2955711T3 (es) 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
US20190307843A1 (en) 2016-11-01 2019-10-10 Cidara Therapeutics, Inc. Single dose methods for preventing and treating fungal infections
US20210002346A1 (en) 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (fr) 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
WO2018187574A1 (fr) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions et procédés de traitement d'infections fongiques
WO2018191692A1 (fr) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
CA3069423C (fr) 2017-07-12 2025-04-15 Napp Pharmaceutical Group Limited Formulations pour le traitement des infections fongiques
US20200164023A1 (en) 2017-08-03 2020-05-28 Cidara Therapeutics, Inc. Methods for preventing and treating intra-abdominal candidiasis
CA3103619A1 (fr) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthese d'un agent antifongique d'echinocandine

Also Published As

Publication number Publication date
FIC20240022I1 (fi) 2024-06-19
US12344680B2 (en) 2025-07-01
JP5809296B2 (ja) 2015-11-10
NL301280I2 (nl) 2024-08-01
HRP20171579T8 (hr) 2018-12-14
DK2680873T3 (en) 2017-10-30
HUE036778T2 (hu) 2018-07-30
SI2680873T1 (sl) 2017-12-29
US20170253635A1 (en) 2017-09-07
CN103889221B (zh) 2016-08-31
CY2024022I1 (el) 2025-03-28
LT2680873T (lt) 2017-11-27
ES2645074T3 (es) 2017-12-04
LUC00351I2 (fr) 2026-05-05
FR24C1027I1 (fr) 2024-08-30
JP6111447B2 (ja) 2017-04-12
EP2680873B1 (fr) 2017-08-09
US20130244930A1 (en) 2013-09-19
PL2680873T3 (pl) 2018-01-31
JP2014516339A (ja) 2014-07-10
HUS2400021I1 (hu) 2024-07-28
SMT201700460T1 (it) 2018-01-11
US20220162263A1 (en) 2022-05-26
EP2680873A2 (fr) 2014-01-08
US20250289852A1 (en) 2025-09-18
CN106279369A (zh) 2017-01-04
JP2017132770A (ja) 2017-08-03
CN106279369B (zh) 2020-02-11
EP3192803A1 (fr) 2017-07-19
EP2680873A4 (fr) 2015-08-26
CY1119709T1 (el) 2018-06-27
CA3053850A1 (fr) 2012-09-07
ES2645074T8 (es) 2018-09-28
JP2016029052A (ja) 2016-03-03
US8722619B2 (en) 2014-05-13
CA2865791C (fr) 2019-10-08
US9217014B2 (en) 2015-12-22
JP6302108B2 (ja) 2018-03-28
CN103889221A (zh) 2014-06-25
WO2012119065A3 (fr) 2014-03-13
EP3192803B1 (fr) 2020-12-09
US20150024997A1 (en) 2015-01-22
NO2680873T3 (fr) 2018-01-06
PT2680873T (pt) 2017-11-01
US20160075740A1 (en) 2016-03-17
JP2018118977A (ja) 2018-08-02
WO2012119065A2 (fr) 2012-09-07
LTPA2024520I1 (fr) 2024-07-10
RS56426B1 (sr) 2018-01-31
CA2865791A1 (fr) 2012-09-07
HRP20171579T1 (hr) 2018-02-09
US9676821B2 (en) 2017-06-13
CY2024022I2 (el) 2025-03-28

Similar Documents

Publication Publication Date Title
FR24C1027I1 (fr) Agents antifongiques et leurs utilisations
IL269045B (en) Aptamers and uses thereof
EP2794654A4 (fr) Anticorps anti-phf-tau et leurs utilisations
EP2885318A4 (fr) Conjugués peptides-dendrimères et leurs utilisations
ME03063B (fr) Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
EP2705039A4 (fr) Inhibiteurs de bromodomaines et leurs utilisations
EP2683406A4 (fr) Anticorps anti-cd40 et leurs utilisations
EP2721031A4 (fr) Inhibiteurs à bromodomaine et leurs utilisations
EP2668210A4 (fr) Anticorps anti-kit et leurs utilisations
EP2906255A4 (fr) Composés anti-sens et leurs utilisations
EP2771020A4 (fr) Dérivés n-acyldipeptides et leurs utilisations
EP2758483A4 (fr) Agents gélifiant pyromellitamides
EP2600878A4 (fr) Lymphocytes b régulateurs et leurs utilisations
EP2888238A4 (fr) Composés benzocyclo-octyne et leurs utilisations
EP2836608A4 (fr) Biomarqueurs de la tuberculose et leurs utilisations
EP2616468A4 (fr) Hétéroaryles condensés et leurs utilisations
EP2718325A4 (fr) Anticorps anti-psgl-1 et leurs utilisations
EP2935283A4 (fr) Inhibiteurs de la glycosidase et leurs utilisations
EP2726103A4 (fr) Anticorps anti-properdine et leurs utilisations
EP2718326A4 (fr) Anticorps contre g-csfr et leurs utilisations
EP2744338A4 (fr) Inhibiteurs de glycosidase sélectifs et leurs utilisations
EP2608785A4 (fr) Lipomacrocycles et leurs utilisations
EP2714023A4 (fr) Nano-ensembles polymères réticulés et leurs utilisations
EP2875014A4 (fr) Médicaments anti-mucus et leurs utilisations
EP2699272A4 (fr) Agents de contraste et utilisations associées